Understanding the Risk of Transmission of HIV, Hepatitis B, and Hepatitis C from U.S. PHS Increased Risk Donors

Summary and Goals

In July 2013, the U.S. Public Health Service (PHS) published new guidelines for reducing human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) transmission during organ transplantation. The federal regulation governing the operations of the Organ Procurement and Transplantation Network (OPTN Final Rule) requires that the OPTN/UNOS Board of Directors develops policies that are consistent with the recommendations of the Centers for Disease Control and Prevention (CDC) regarding testing potential organ donors and following transplant recipients to prevent donor-to-recipient transmission of infection. Subsequently, the Board voted to modify existing OPTN/UNOS policies defining which groups qualify as increased risk donors, and to require nucleic acid testing (NAT) of all donors for HCV. Additionally, the Board required NAT or antigen/antibody (Ag/Ab) combination HIV testing for increased risk donors.

Since implementation of the new policies, the number of potential deceased donors classified as increased risk has increased to almost one in five donors nationally. Research studies have demonstrated that organs from donors classified as increased risk are less likely to be used than organs from non-increased risk donors. This finding persists despite the fact that post-transplant graft and patient survival with increased risk organs is equal to or better than that with non-increased risk organs.

When a person becomes infected, it takes some time for the infection to be detected in the body; this is called the "window period". The use of NAT markedly shortens the window period. Survey data have demonstrated that most non-physician transplant providers would like further education regarding the risk of infection associated with increased risk donors. Survey data also show that patients have limited understanding and many misconceptions regarding the definition and implications of the increased risk designation.

Accordingly, the OPTN/UNOS Disease Transmission Advisory Committee (DTAC), the American Society of Transplantation (AST), the American Society of Transplant Surgeons (ASTS), and the North American Transplant Coordinators Organization (NATCO) provide this guidance document to help transplant professionals better understand the low risk of window period infection present in PHS increased risk donors.

This resource tool is intended to give educational support for Organ Procurement Organizations (OPOs) and transplant hospitals and is for voluntary use by members. This resource is not OPTN policy, so it does not carry the monitoring or enforcement implications of policy. It is not an official guideline for clinical practice, nor is it intended to be clinically prescriptive or to define a standard of care.

Executive Summary

The following summary is provided to help transplant professionals accurately counsel potential organ transplant candidates on the relative risks associated with donors classified as PHS increased risk.

- The increased risk donor classification serves principally to identify those donors most at risk of having recent infection with HIV, HBV, or HCV.
- Increased risk donor classification does not mean that the organ is of lower quality.
- Choosing to accept an organ from an increased risk donor entails balancing donor and recipient characteristics. In many cases, the risks of declining such an organ offer may be greater than the risk of donor-derived viral infection.
- The risk of window period infection with HIV, HBV, or HCV, and therefore the risk of virus transmission from donor to recipient, is extremely small if a risk behavior occurred more than three weeks prior to NAT.
- There is wide variation in viral transmission risk even within donors classified as increased risk donors. Donors with a history of incarceration or less safe sexual practices are generally much lower risk than donors with a history of intravenous drug use (IVDU).
- Even under the highest risk behavior, the risk of HIV, HBV, or HCV transmission from a NAT negative donor organ is low (around 1% or less).
- Ultimately, with appropriate counselling and informed consent, we aim to maximize organ availability.

Window Periods with Serologic and Nucleic Acid Testing

Persons who had developed a HIV, HBV, or HCV infection several months prior to organ donation would be discovered by the routine serological (antibody) tests performed on all potential donors. However, there is the chance that exposure to HIV, HBV, or HCV in the days immediately prior to death could not be detected by serological (antibody) tests due to insufficient amount of antibodies against a specific virus. Additionally, substantial blood loss and hemodilution can also create an environment for false negative serological test results.
The concept of “increased risk” (previously referred to as “high risk”) donors was created to identify such a population of deceased or living donors potentially at risk for recent acquisition of HIV or viral hepatitis. These recently infected donors would therefore be capable of inadvertently transmitting the virus to recipients, yet would appear negative on serologic testing. Importantly, most increased risk donors will be truly negative for each of these infections, and the classification does in no way reflect the quality of the organs donated.

Nucleic Acid Testing, which has been used with increasing frequency over the last decade, is now required by OPTN Policy (for HCV and HIV) for all increased risk donors. The NAT window period is very short, so NAT testing can result positive much closer to the time of infection compared to serological testing. Behaviors resulting in transmissible infection would have had to occur within 5-6 days (HIV) or 3-5 days (HCV) before blood samples were obtained for disease screening. The window period for HBV (20-22 days) is longer than for HIV and HCV. The Table 1 below describes the time from infection to detection associated with different serological or NAT methods.

Table 1: Estimates of window period length for different testing methods

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Standard Serology</th>
<th>Enhanced Serology (fourth generation or combined antibody-antigen tests)</th>
<th>Nucleic Acid Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>17-22 days (5-8)</td>
<td>~7-16 days (9, 10)</td>
<td>5-6 days (5,6)</td>
</tr>
<tr>
<td>HCV</td>
<td>~70 days (5, 8, 11)</td>
<td>~40-50 days (12-14)</td>
<td>3-5 days (5, 11)</td>
</tr>
<tr>
<td>HBV</td>
<td>35-44 days (15, 16)</td>
<td>Not applicable</td>
<td>20-22 days (8,15)</td>
</tr>
</tbody>
</table>

*Window period = time to detection of infection by a specific testing method. HIV, HCV, and HBV NAT data are listed for the most sensitive NAT currently used in blood-donor screening (Gen Probe TMA for HIV and HCV, and Roche Cobas MPX for HBV on individual donation); the window period will be longer if less sensitive NAT is used for donor screening. HIV- and HCV-antibody and HBV surface antigen data are for tests licensed and current used in blood-donor screening (enzyme immunoassays or chemiluminescent assays). Window period estimates for fourth generation assays are derived from more limited data and show substantial variation with different manufacturer’s test kits.

Changes to Increased Risk Donor Definition

Prior to the 2013 PHS guideline, the 1994 guideline was intended to identify risk factors for HIV only. Table 2 below summarizes the differences between the 1994 and 2013 increased risk donor guidelines criteria:

Table 2: Comparison of 1994 CDC High Risk and 2013 U.S. PHS Increased Risk Guidelines

<table>
<thead>
<tr>
<th>1994 Guideline</th>
<th>2013 Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSM* in the preceding 5 years</td>
<td>MSM in the preceding 12 months</td>
</tr>
<tr>
<td>Non-medical injection drug use in preceding 5 years</td>
<td>Non-medical injection drug use in preceding 12 months</td>
</tr>
<tr>
<td>Sex in exchange for money/drugs in preceding 5 years</td>
<td>People who have had sex in exchange for money or drugs in the preceding 12 months</td>
</tr>
<tr>
<td>People who have had sex with a person known or suspected to have HIV infection in the preceding 12 months</td>
<td>People who have had sex with a person known or suspected to have HIV, HBV, or HCV infection in the preceding 12 months</td>
</tr>
<tr>
<td>Women who have had sex with a man with a history of MSM behavior in the preceding 12 months</td>
<td>Women who have had sex with a man with a history of MSM behavior in the preceding 12 months</td>
</tr>
<tr>
<td>People who have had sex with a person who had sex in exchange for money or drugs in the preceding 12 months</td>
<td>People who have had sex with a person who had sex in exchange for money or drugs in the preceding 12 months</td>
</tr>
</tbody>
</table>

7 OPTN Policy 2.9 (Required Deceased Donor Infectious Disease Testing)
The transition from the 1994 to 2013 guideline occurred between August 2013 and February 2014. Beginning in February 2014, only the new guideline could be used. The percentage of donors classified as increased risk donors who had organs procured increased from 12.3% to 19.5%, and exceeded 25% in 14 OPOs. The exact reasons for this increase are unknown, but may be related to increased numbers of potential donors who died from opioid overdoses.

### Risk Associated with Specific Exposures

As described above, a potential donor may be labeled as increased risk for a variety of different exposures, and these exposures carry very different risks of transmitting recent infection with HIV, HBV, or HCV. For example, a potential donor who was in a county jail 10 months ago for a period of 3 days would be at much lower risk of acquiring HCV or HIV in the preceding week as compared to a potential donor whose cause of death was opioid overdose from IVDU. Table 3 below is based on modeling data and describes the estimated risk of window period infection (both as risk per 10,000 donors and as a percentage). The table is designed to estimate the average risk irrespective of when the test was

---

<table>
<thead>
<tr>
<th>1994 Guideline</th>
<th>2013 Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>People who have had sex with a person who injected drugs by intravenous, intramuscular, or subcutaneous route for nonmedical reasons in the preceding 12 months</td>
<td>People who have had sex with a person who injected drugs by intravenous, intramuscular, or subcutaneous route for nonmedical reasons in the preceding 12 months</td>
</tr>
<tr>
<td>A child who is ≤18 months of age and born to a mother known to be infected with, or at increased risk for HIV infection (should not be used)</td>
<td>A child who is ≤18 months of age and born to a mother known to be infected with, or at increased risk for HIV, HBV, or HCV infection</td>
</tr>
<tr>
<td>A child who has been breastfed in the past 12 months by a mother known to have or at risk for HIV infection</td>
<td>A child who has been breastfed within the preceding 12 months and the mother is known to be infected with, or at increased risk for, HIV infection</td>
</tr>
<tr>
<td>Inmates of correctional systems</td>
<td>People who have been in lockup, jail, prison, or a juvenile correctional facility for more than 72 consecutive hours in the preceding 12 months</td>
</tr>
<tr>
<td>Persons whose history or physical, exam, medical records, or laboratory reports indicate sexually transmitted disease</td>
<td>People who have been newly diagnosed with, or have been treated for, syphilis, gonorrhea, Chlamydia, or genital ulcers in the preceding 12 months</td>
</tr>
<tr>
<td>Not listed</td>
<td>People who have been on hemodialysis in the preceding 12 months (hepatitis C only)</td>
</tr>
<tr>
<td>Not listed</td>
<td>When a deceased potential organ donor’s medical/behavioral history cannot be obtained or risk factors cannot be determined, the donor should be considered at increased risk for HIV, HBV, and HCV infection because the donor’s risk for infection is unknown</td>
</tr>
<tr>
<td>Persons who cannot be tested for HIV infection because of refusal, inadequate blood samples (e.g. hemodilution that could result in false-negative tests), or any other reasons</td>
<td>When a deceased potential organ donor’s blood specimen is hemodiluted, the donor should be considered at increased risk for HIV, HBV, and HCV infection because the donor’s risk for infection is unknown</td>
</tr>
</tbody>
</table>

---

*MSM=men who have sex with men

completed (remote infection should result in a positive antibody test). The ELISA columns refer to the number of donors in the serological window period based on serology (antibody) testing only; the NAT columns refer to the number of donors with negative NAT who are in the NAT window period. NAT reduces the risk of serological window period infection by about 10-fold for most exposures.

Even with NAT, there is still some risk of transmission. However, not all donors with the PHS characteristics carry the same risk of window period infection. For example, donors with recent IVDU with negative serological testing still have a risk of undetected HCV of 300.6 per 10,000 donors (3%). Having both negative serology and negative NAT reduces this risk to 32.4 out of 10,000 donors (0.3%). In contrast, donors with a history of incarceration within the previous 12 months and negative NAT and serology testing would have only a 0.8 per 10,000 donors (0.008%) risk of infection with transmissible HCV.

Table 3: Estimated risk of window period infection (per 10,000 donors)

<table>
<thead>
<tr>
<th>Risk per 10,000 donors</th>
<th>HIV ELISA</th>
<th>HIV NAT</th>
<th>HCV ELISA</th>
<th>HCV NAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men who have sex with men</td>
<td>10.2 (0.10%)</td>
<td>4.2 (&lt;0.1%)</td>
<td>32.5 (0.33%)</td>
<td>3.5 (&lt;0.1%)</td>
</tr>
<tr>
<td>IV drug users</td>
<td>12.1 (0.12%)</td>
<td>4.9 (&lt;0.1%)</td>
<td>300.6 (3%)</td>
<td>32.4 (0.32%)</td>
</tr>
<tr>
<td>Persons with hemophilia</td>
<td>0.086 (&lt;0.01%)</td>
<td>0.035 (&lt;0.01%)</td>
<td>0.26 (&lt;0.1%)</td>
<td>0.027 (&lt;0.01%)</td>
</tr>
<tr>
<td>Commercial sex worker</td>
<td>6.6 (&lt;0.1%)</td>
<td>2.7 (&lt;0.1%)</td>
<td>114.9 (1.2%)</td>
<td>12.3 (0.12%)</td>
</tr>
<tr>
<td>Sex with a partner in above categories</td>
<td>0.7 (&lt;0.1%)</td>
<td>0.3 (&lt;0.1%)</td>
<td>114.9 (1.2%)</td>
<td>12.3 (0.12%)</td>
</tr>
<tr>
<td>Blood product exposure</td>
<td>1.5 (&lt;0.1%)</td>
<td>0.6 (&lt;0.1%)</td>
<td>4 (&lt;0.1%)</td>
<td>0.4 (&lt;0.1%)</td>
</tr>
<tr>
<td>Incarceration</td>
<td>2.3 (&lt;0.1%)</td>
<td>0.9 (&lt;0.1%)</td>
<td>7.2 (&lt;0.1%)</td>
<td>0.8 (&lt;0.1%)</td>
</tr>
</tbody>
</table>

Even with the increased sensitivity offered by NAT, this testing may not, for example, detect an HCV exposure that occurred several days prior to testing. Accordingly, a donor that died with an immediate needle exposure has a risk significantly higher than NAT may reflect, possibly as high as 3% for HCV, although lower for HBV and HIV. Figure 1 illustrates the probability of undetected HCV infection after a known IVDU exposure, despite negative NAT results.

---


Disclosure of the donor's risk behavior is currently up for debate. Even without disclosing the specific behavior of the donor that results in the increased risk designation, the actual comparative risk associated with that behavior should be communicated by the transplant team when informing a transplant candidate about the various risks associated with accepting an offered organ to optimize recipient’s informed consent.

Risk can also be explained to patients relating to everyday concepts, as well as by using resources available. Figure 2 below, as well as a link to the National Safety Council provided in the footnotes, outlines the lifetime risk of death in a traffic accident. This information can help laypersons understand the relative risk of undetected disease transmission.

Figure 1: Probability of Undetected HCV Infection despite Negative Nucleic Acid Testing due to isolated IVDU Increased Risk Behavior

---


The InformMe website provides further animations and graphics to allow patients to understand the risk associated with accepting an organ from a donor bearing the PHS characteristics associated with higher risk of HIV, HBV or HCV infection. Further, recipients who receive organs from donors with these characteristics should be informed that they will be monitored post-transplant for infection with HIV, HBV, and HCV.

Consequences of Transmission of HIV, Hepatitis B, and Hepatitis C

As treatments for HIV, HBV, and particularly HCV, have improved, the medical consequences of donor-derived infection have lessened. Solid organ transplantation of organs from donors who have screened negative for HIV into selected recipients living with HIV infection prior to transplant has become standard. Overall graft and recipient survival in HIV mono-infected recipients is similar to HIV negative recipients. Current treatments for HCV have demonstrated high cure rates in the post-transplant setting in those infected with HCV pre-transplant. HBV, if chronic infection develops, can be successfully suppressed. Nonetheless, the psychological consequence of donor-derived infection, particularly HIV, may have significant impact on recipient quality of life. Finally, if appropriate monitoring is not conducted after

---


transplantation and donor-derived infection is not recognized early, significant clinical consequences may occur and treatment of the infection may be less efficacious.

**Risk of Declining the Organ from a Donor with the PHS Characteristics for Increased Risk of HIV, HCV or HBV Infection and Remaining on the Waiting List**

In communicating the risk of donor-derived infection from any donor, including those associated with donors bearing the behavioral risk factors identified by the PHS, it is important to consider the risks to the potential recipient of not accepting that organ and continuing to wait for another offer. This risk-benefit calculation should be individualized, based on organ type, underlying disease, and patient factors, such as blood type and immunologic profile. Local organ wait times also vary. For example, the Scientific Registry for Transplant Recipients (SRTR) reported that waiting list mortality rates varied by DSA from approximately two to eight deaths occurring per year for every 100 candidates on the kidney transplant waitlist in 2015.18

The Johns Hopkins Increased Risk Donor Tool uses model-based predictions to calculate risks based on particular recipient characteristics.19 In one analysis of candidates on the kidney waiting list, accepting or declining an increased risk donor organ resulted in five year survival differences that varied from 6.4% to +67.3% depending on specific recipient characteristics.20 The risks of continuing to wait are likely even greater for liver or heart candidates.21 Given the recent availability of highly effective HCV treatments, older estimates may overestimate mortality associated with HCV transmission. The InformMe website (https://informme.cbits.northwestern.edu) provides further context to help potential recipients weigh the risks and benefits of accepting organs from donors with increased risk behavioral characteristics, and an online calculator is available.22

**Risk of Acquiring Hepatitis C While on Dialysis**

Declining an organ bearing a risk of disease transmission will prolong time on dialysis for a patient with kidney failure, and, as hemodialysis is a risk for HBV and HCV, may paradoxically result in an increased risk of acquiring viral hepatitis. Vaccination, however, can substantially reduce the risk of HBV. No vaccine is available for HCV, and the incidence of HCV on hemodialysis is estimated to be 0.34% per year, or 1 in 3,000.23 This risk is roughly similar to the one-time risk of acquiring HCV from an organ donor with active IVDU (the highest risk category). Therefore, in some instances, the risk of acquiring HCV can be greater by declining an organ from an increased risk donor.

**Limitations to Current Screenings**

Donor screening cannot detect all transmissible infections. DTAC review of reported data between 2008 and 2016 revealed 15 cases of donor-derived HCV. Four cases were likely related to human or testing error. The remaining 11 occurred as window period infections; four in the serologic window period and seven increased risk donors in a NAT window period. Intravenous drug use was identified as the cause of

---


19 http://transplantmodels.com/ird/


22 https://informme.cbits.northwestern.edu

death in four of these 15 donors; three from 2016, and one from 2012\textsuperscript{24}. There have been no cases of HIV transmission since the PHS Increased Risk guidelines were changed in 2013.

In addition to the limitations associated with laboratory testing, determining if a potential donor should be classified as actually having a risk behavior of interest is challenging. In the setting of deceased donation, information is typically obtained from family members or friends who may have limited knowledge of donor behaviors. Consequently, patients should be made aware that no transplant is truly risk free, yet the benefits of transplant often outweigh these risks.

Pediatric Organ Transplant Considerations

There may be unique considerations when evaluating an increased risk pediatric donor. The benefits of accepting an increased risk donor organ should be weighed against pediatric specific organ, and disease mortality and morbidity data, where possible. Though in smaller numbers as compared to adult deceased donors, OPTN data does note an increase in pediatric deceased donors that met increase risk guidelines during the period of 2005-2016.\textsuperscript{25} During the same period, there was an increase in transplants performed on pediatric recipients using organs from increased risk deceased donors, up from 4.5% to 10.6%. There have been no reported transmissions involving HIV, HBV, or HCV from pediatric organ donors. Furthermore, no cases of donor-derived HIV or HCV have been identified in pediatric recipients.\textsuperscript{26} Having said this, less is known about treatment options, particularly for HCV infected pediatric transplant recipients, should infection occur.

Conclusion

Through this guidance, transplant professionals can better understand and communicate the risk of window period infection present in PHS increased risk donors compared with the benefits of transplant to our community. This guidance will be reviewed periodically to ensure clinical relevance and currency.


\textsuperscript{25} Based on OPTN data as of April 7, 2017